In INSTRIDE 1, similar baseline levels and changes from baseline in ADA incidence, relative antibody levels, incidence of ADA cross-reactivity to human insulin, and drug-specific ADA were observed throughout the time points of the study in patients with type 1 diabetes treated with MYL-1501D and reference insulin glargine. This evidence concerns the gene ADA and type 1 diabetes mellitus.